NOVAVAX INC Accounts Payable
NOVAVAX INC (NVAX) had Accounts Payable of $22.94 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-06
- 2026-06-30: Accounts Payable, Current $22.94M.
- 2026-03-31: Accounts Payable, Current $16.10M.
- 2025-12-31: Accounts Payable, Current $24.58M.
- 2025-09-30: Accounts Payable, Current $15.23M.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-06-30 | $22.94M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $16.10M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $24.58M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $15.23M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $50.59M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $34.16M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $41.58M 10-K · filed 2026-02-26 |
| 2024-09-30 | $57.52M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $79.96M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $57.72M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $132.61M 10-K · filed 2025-02-27 |
| 2023-09-30 | $101.91M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $87.25M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $124.80M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $216.52M 10-K · filed 2024-02-28 |
| 2022-09-30 | $145.00M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $386.49M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $135.13M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $127.05M 10-K · filed 2023-02-28 |
| 2021-09-30 | $59.56M 10-Q · filed 2021-11-05 |
| 2021-06-30 | $74.00M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $113.61M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $54.33M 10-K · filed 2022-03-01 |
| 2020-09-30 | $15.10M 10-Q · filed 2020-11-10 |
| 2020-06-30 | $9.24M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $2.52M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $2.91M 10-K · filed 2021-03-01 |
| 2019-09-30 | $4.21M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $4.30M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $6.15M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $9.30M 10-K · filed 2020-03-11 |
| 2018-09-30 | $6.79M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $6.69M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $5.77M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $5.61M 10-K · filed 2019-03-18 |
| 2017-09-30 | $5.24M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $8.02M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $3.79M 10-Q · filed 2017-05-08 |
| 2016-12-31 | $5.68M 10-K · filed 2018-03-14 |
| 2016-09-30 | $16.23M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $15.99M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $11.24M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $11.89M 10-K · filed 2017-02-27 |
| 2015-09-30 | $8.20M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $7.12M 10-Q · filed 2015-08-10 |
| 2015-03-31 | $9.74M 10-Q · filed 2015-05-07 |
| 2014-12-31 | $12.91M 10-K · filed 2016-02-29 |
| 2014-09-30 | $2.98M 10-Q · filed 2014-11-06 |
| 2014-06-30 | $4.50M 10-Q · filed 2014-08-07 |
| 2014-03-31 | $4.02M 10-Q · filed 2014-05-08 |
| 2013-12-31 | $5.99M 10-K · filed 2015-02-27 |
| 2013-09-30 | $3.34M 10-Q · filed 2013-11-12 |
| 2013-06-30 | $2.95M 10-Q · filed 2013-08-08 |
| 2013-03-31 | $2.17M 10-Q · filed 2013-05-09 |
| 2012-12-31 | $3.23M 10-K · filed 2014-03-12 |
| 2012-09-30 | $2.20M 10-Q · filed 2012-11-09 |
| 2012-06-30 | $3.38M 10-Q · filed 2012-08-09 |
| 2012-03-31 | $2.96M 10-Q · filed 2012-05-09 |
| 2011-12-31 | $2.65M 10-K · filed 2013-03-12 |
| 2011-09-30 | $2.40M 10-Q · filed 2011-11-08 |
| 2011-06-30 | $2.96M 10-Q · filed 2011-08-09 |
| 2010-12-31 | $3.57M 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |